jump to content jump to footer
- 37 minute(s)

Clinical trial excellence for routine covid-19 assessment

Mint Medical is on the front lines in the fight against COVID-19, proving that radiology can act as a role model for gathering evidence by utilizing structured data.
 
In this webcast, Prof. Dr. Maria-Katharina Ganten and Gabriel Salg highlight the urgent need for structured data collection, as well as the importance of data quality, integrity, and traceability. The hosts discuss how to support trial compatible data acquisition in routine work by example of a European multicenter project.
 
Prof. Ganten and Mr. Salg also provide a look to the future in which radiology has the opportunity to set standards for new research strategies, not only concerning COVID studies but rather for any disease or treatment.

Radiologist reviewing whole-body MRI images with AI-supported tumor burden quantification for bone metastases and multiple myeloma using mint Lesion.
Mint Medical has integrated an AI algorithm developed by The Institute of Cancer Research and The Royal Marsden into mint Lesion. The solution supports bone disease assessment and treatment response evaluation in advanced prostate cancer and multiple myeloma.
The ICR and The Royal Marsden work with Mint Medical to integrate AI-powered software into cancer treatment
The Institute of Cancer Research (ICR), London, and The Royal Marsden NHS Foundation Trust have announced a new licensing agreement with MedTech…
Read more
A collaborative session between a radiologist and an investigator analyzing multicentric trial progress and quantitative imaging data on a centralized dashboard.
Integrated Data Management for Multicentric Imaging in Investigator-Initiated Trials (IITs)
Establishing a Framework for Multicentric Data Coordination For many investigators, the transition from a single-site study to a multicentric model…
Read more
mint Lesion usage during a clinical trial read, featuring the TGRM export tool.
Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer
For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…
Read more
scroll-top